Zuclopenthixol-induced neuroleptic malignant syndrome in an adolescent girl

Basit Öğe Kaydı
dc.contributor.authorErermis, Serpil
dc.contributor.authorBildik, Tezan
dc.contributor.authorTamar, Muge
dc.contributor.authorGockay, Ahmet
dc.contributor.authorKarasoy, Hatice
dc.contributor.authorErcan, Eyup Sabri
dc.date.accessioned2019-10-27T19:37:18Z
dc.date.available2019-10-27T19:37:18Z
dc.date.issued2007
dc.departmentEge Üniversitesien_US
dc.description.abstractWe present the case of a 14-year-old female who had many characteristics of neuroleptic malignant syndrome (NMS) without pyrexia following a single depot injection of 200 mg of zuclopenthixol. The patient presented with a change in mental status that had progressed over the preceding 48 hours. Subsequently, she became increasingly agitated and confused, and developed diffuse muscular rigidity, mutism, tremor, tachycardia, diaphoresis, sialorrhea, and incontinence. Results of laboratory tests showed elevated CPK levels, leukocytosis, and a low serum iron level. Bromocriptine and diazepam were used as initial treatment of a probable NMS and provided significant improvement. During the next seven days, she clinically improved but continued to exhibit emotional lability, logorrhea, elevated mood, and increased psychomotor activity. Therefore, bromocriptine and diazepam were discontinued and lorazepam and lithium were administered as treatment of a bipolar disorder. Four weeks later, she was discharged in stable condition. The presentation of this case report suggests that the primary pyschiatric diagnosis is important in antipsychotic usage in the pediatric population, and that young patients receiving neuroleptic treatment should be monitored for the early signs of NMS. Using the diagnostic criteria of a neuroleptic toxicity spectrum may result in greater clinical awareness and earlier recognition of NMS.en_US
dc.identifier.doi10.1080/15563650601031692en_US
dc.identifier.endpage280en_US
dc.identifier.issn0731-3810
dc.identifier.issue3en_US
dc.identifier.pmid17453880en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.startpage277en_US
dc.identifier.urihttps://doi.org/10.1080/15563650601031692
dc.identifier.urihttps://hdl.handle.net/11454/39958
dc.identifier.volume45en_US
dc.identifier.wosWOS:000245923600009en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherTaylor & Francis Incen_US
dc.relation.ispartofClinical Toxicologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectneuroleptic malignant syndrome (NMS)en_US
dc.subjectzuclopenthixolen_US
dc.subjectantipsychotic agentsen_US
dc.subjectchilden_US
dc.subjectadolescentsen_US
dc.titleZuclopenthixol-induced neuroleptic malignant syndrome in an adolescent girlen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu